OncoZenge AB (publ)
Stockholm Stock ExchangeTotal Valuation
OncoZenge AB (publ) carries a market capitalization of 97.77M, placing it among publicly traded companies globally. Its enterprise value stands at 82.08M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 97.77M |
| Enterprise Value | 82.08M |
Share Statistics
OncoZenge AB (publ) currently has 11.71M shares outstanding.
| Shares Outstanding | 11.71M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 30.83, and the price-to-book ratio stands at -1.09.
| PE Ratio | N/A |
| PS Ratio | 30.83 |
| PB Ratio | -1.09 |
| P/TBV Ratio | 13.99 |
| P/FCF Ratio | -13.91 |
| P/OCF Ratio | -13.91 |
Enterprise Valuation
| EV / Sales | 30.25 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
OncoZenge AB (publ) maintains a current ratio of 0.97, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.97 |
| Quick Ratio | 0.64 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -1,136.17 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -45.18 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 8.38 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
OncoZenge AB (publ)'s stock has gained approximately 13.91162% over the past 52 weeks. The 50-day moving average sits at 6.92, while the 200-day moving average is 6.11.
| Beta (5Y) | N/A |
| 52-Week Price Change | 13.91162% |
| 50-Day Moving Average | 6.92 |
| 200-Day Moving Average | 6.11 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, OncoZenge AB (publ) generated 2.71M in revenue and converted that into -6.82M in net income, yielding earnings per share of -0.58. EBITDA reached -6.82M, while operating income came in at -6.82M.
| Revenue | 2.71M |
| Gross Profit | N/A |
| Operating Income | -6.82M |
| Pretax Income | -6.82M |
| Net Income | -6.82M |
| EBITDA | -6.82M |
| EBIT | -6.82M |
| Earnings Per Share (EPS) | -0.58 |
Balance Sheet
Total book value stands at -77.02M, with working capital of -67,000.00 providing operational flexibility.
| Cash & Cash Equivalents | 1.56M |
| Total Debt | N/A |
| Net Debt | -1.56M |
| Equity (Book Value) | -77.02M |
| Book Value Per Share | -6.58 |
| Working Capital | -67,000.00 |
Cash Flow
OncoZenge AB (publ) produced -6.01M in operating cash flow over the past twelve months.
| Operating Cash Flow | -6.01M |
| Capital Expenditures | N/A |
| Free Cash Flow | -6.01M |
| FCF Per Share | -0.51 |
Margins
OncoZenge AB (publ) operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -251.27 and net profit margin of -251.49 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -251.27 |
| Pretax Margin | -251.49 |
| Profit Margin | -251.49 |
| EBITDA Margin | -251.27 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | -7.19 |
Stock Splits
OncoZenge AB (publ)'s most recent stock split took place on February 16, 2021 with a 500:621 split ratio.
| Last Split Date | 2/16/2021 |
| Split Ratio | 500:621 |
Scores
OncoZenge AB (publ) posts an Altman Z-Score of 5.18, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.18 |